United States Biotechnology & Medical Research

Foamix Pharmaceuticals Ltd (FOMX)

Track

Track

Ticker: FOMX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Hadar Ilan CFO & Country Manager
Transaction date
Planned sale
Price
192.61
Quantity 99,878 -47.7%
Value US$2,652,329
Hadar Ilan CFO & Country Manager
Transaction date
Planned sale
Price
88.17
Quantity 23,228 -30.6%
Value US$4,139,045
KAZANCHYAN ANNA Non-Executive Director
Transaction date
Sale
Price
227.47
Quantity 87,035 +39.6%
Value US$1,132,986
KAZANCHYAN ANNA
Transaction date
Planned sale
Price
2.31
Quantity 808 -1.8%
Value US$1,866
Harsch Mutya CLO and General Counsel
Transaction date
Sale
Price
2.35
Quantity 639 -1.2%
Value US$1,502
2.8
Stuart Iain Chief Scientific Officer
Transaction date
Sale
Price
2.35
Quantity 951 -1.5%
Value US$2,235
3.2
Domzalski David CEO Executive Director
Transaction date
Sale
Price
2.35
Quantity 3,355 -1.6%
Value US$7,884
KAZANCHYAN ANNA Non-Executive Director
Transaction date
Planned sale
Price
2.61
Quantity 10,600 -18.9%
Value US$27,666
2.8
Stuart Iain Chief Scientific Officer
Transaction date
Sale
Price
3.75
Quantity 1,696 -2.6%
Value US$6,360
Harsch Mutya CLO and General Counsel
Transaction date
Sale
Price
3.75
Quantity 2,519 -4.6%
Value US$9,446
3.2
Domzalski David CEO Executive Director
Transaction date
Sale
Price
3.75
Quantity 5,096 -2.3%
Value US$19,110
Wiley Matthew T. Chief Commercial Officer
Transaction date
Purchase
Price
3.76
Quantity 13,440 +26.9%
Value US$50,534
Domzalski David CEO Executive Director
Transaction date
Sale
Price
4.05
Quantity 68 -0.0%
Value US$275
Schwartz Aharon Non-Executive Director
Transaction date
Purchase
Price
3.88
Quantity 12,200 +12.2%
Value US$47,373
Schwartz Aharon Non-Executive Director
Transaction date
Purchase
Price
3.92
Quantity 50,000 +100.0%
Value US$195,800
Schwartz Aharon Non-Executive Director
Transaction date
Purchase
Price
3.89
Quantity 50,000 +inf%
Value US$194,600
Domzalski David CEO Executive Director
Transaction date
Sale
Price
3.90
Quantity 5,036 -3.3%
Value US$19,640
Howard Alvin D VP Regulatory Officer
Transaction date
Sale
Price
3.90
Quantity 3,375 -8.1%
Value US$13,162
Domzalski David CEO Executive Director
Transaction date
Sale
Price
4.58
Quantity 2,062 -1.3%
Value US$9,444
Stuart Iain SVP R&D Officer
Transaction date
Sale
Price
4.58
Quantity 683 -2.0%
Value US$3,128
Domzalski David CEO Executive Director
Transaction date
Sale
Price
5.81
Quantity 601 -0.4%
Value US$3,492
Elliott Russell P. VP Drug Development Officer
Transaction date
Sale
Price
5.81
Quantity 142 -1.1%
Value US$825
Howard Alvin D VP Regulatory Officer
Transaction date
Sale
Price
5.81
Quantity 234 -0.6%
Value US$1,360
Domzalski David CEO Executive Director
Transaction date
Sale
Price
5.67
Quantity 67 -0.0%
Value US$380
Domzalski David CEO Executive Director
Transaction date
Sale
Price
5.68
Quantity 8,238 -5.1%
Value US$46,792
Stuart Iain SVP R&D Officer
Transaction date
Sale
Price
5.68
Quantity 2,715 -7.3%
Value US$15,421
Domzalski David CEO Executive Director
Transaction date
Sale
Price
5.10
Quantity 602 -0.4%
Value US$3,070
Elliott Russell P. VP Drug Development Officer
Transaction date
Sale
Price
5.10
Quantity 142 -1.1%
Value US$724
Howard Alvin D VP Regulatory Officer
Transaction date
Sale
Price
5.10
Quantity 234 -0.6%
Value US$1,193
Domzalski David CEO Executive Director
Transaction date
Sale
Price
5.26
Quantity 67 -0.0%
Value US$352
Hirsch Stanley Non-Executive Director
Transaction date
Sale
Price
5.09
Quantity 6,164 -48.6%
Value US$31,369
Howard Alvin D VP Regulatory Officer
Transaction date
Sale
Price
5.08
Quantity 234 -0.6%
Value US$1,189
Elliott Russell P. VP Drug Development Officer
Transaction date
Sale
Price
5.08
Quantity 142 -1.1%
Value US$721
Domzalski David CEO Executive Director
Transaction date
Sale
Price
5.08
Quantity 602 -0.4%
Value US$3,058
Elliott Russell P. VP Drug Development
Transaction date
Sale
Price
6.14
Quantity 817 -6.0%
Value US$5,016
Domzalski David CEO Executive Director
Transaction date
Sale
Price
5.95
Quantity 66 -0.0%
Value US$393
Eini Meir
Transaction date
Planned sale
Price
6.33
Quantity 5,000 -0.2%
Value US$31,658
Eini Meir
Transaction date
Planned sale
Price
6.05
Quantity 5,000 -0.2%
Value US$30,227
Eini Meir
Transaction date
Planned sale
Price
6.10
Quantity 5,000 -0.2%
Value US$30,520
Eini Meir
Transaction date
Planned sale
Price
6.17
Quantity 5,000 -0.2%
Value US$30,850
Eini Meir
Transaction date
Planned sale
Price
6.58
Quantity 5,000 -0.2%
Value US$32,882
Eini Meir
Transaction date
Planned sale
Price
6.68
Quantity 5,000 -0.2%
Value US$33,411
Eini Meir
Transaction date
Planned sale
Price
6.26
Quantity 5,000 -0.2%
Value US$31,310
Eini Meir
Transaction date
Planned sale
Price
6.18
Quantity 5,000 -0.2%
Value US$30,902
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2019-09-11 2019-09-10 PlS Planned sale
Hadar Ilan

CFO & Country Manager
99,878 -47.7%
192.61
US$2,652,329 		99,878 -47.7% 192.61 US$2,652,329
2019-09-11 2019-09-09 PlS Planned sale
Hadar Ilan

CFO & Country Manager
23,228 -30.6%
88.17
US$4,139,045 		23,228 -30.6% 88.17 US$4,139,045
2019-08-28 2019-08-26 S Sale KAZANCHYAN ANNA Non-Executive Director
87,035 +39.6%
227.47
US$1,132,986 		87,035 +39.6% 227.47 US$1,132,986
2019-07-17 2019-07-15 PlS Planned sale
KAZANCHYAN ANNA
808 -1.8%
2.31
US$1,866 		808 -1.8% 2.31 US$1,866
2019-07-03 2019-07-01 S Sale
Harsch Mutya

CLO and General Counsel
639 -1.2%
2.35
US$1,502 		639 -1.2% 2.35 US$1,502
2019-07-03 2019-07-01 S Sale
2.8
Stuart Iain

Chief Scientific Officer
951 -1.5%
2.35
US$2,235 		951 -1.5% 2.35 US$2,235
2019-07-03 2019-07-01 S Sale
3.2
Domzalski David

CEO

Executive Director
3,355 -1.6%
2.35
US$7,884 		3,355 -1.6% 2.35 US$7,884
2019-05-20 2019-05-20 PlS Planned sale
KAZANCHYAN ANNA
Non-Executive Director
10,600 -18.9%
2.61
US$27,666 		10,600 -18.9% 2.61 US$27,666
2019-04-03 2019-04-01 S Sale
2.8
Stuart Iain

Chief Scientific Officer
1,696 -2.6%
3.75
US$6,360 		1,696 -2.6% 3.75 US$6,360
2019-04-03 2019-04-01 S Sale
Harsch Mutya

CLO and General Counsel
2,519 -4.6%
3.75
US$9,446 		2,519 -4.6% 3.75 US$9,446
2019-04-03 2019-04-01 S Sale
3.2
Domzalski David

CEO

Executive Director
5,096 -2.3%
3.75
US$19,110 		5,096 -2.3% 3.75 US$19,110
2019-03-06 2019-03-05 B Purchase
Wiley Matthew T.

Chief Commercial Officer
13,440 +26.9%
3.76
US$50,534 		13,440 +26.9% 3.76 US$50,534
2018-12-06 2018-12-03 S Sale Domzalski David

CEO

Executive Director
68 -0.0%
4.05
US$275 		68 -0.0% 4.05 US$275
2018-12-06 2018-11-28 B Purchase Schwartz Aharon Non-Executive Director
12,200 +12.2%
3.88
US$47,373 		12,200 +12.2% 3.88 US$47,373
2018-12-06 2018-11-27 B Purchase Schwartz Aharon Non-Executive Director
50,000 +100.0%
3.92
US$195,800 		50,000 +100.0% 3.92 US$195,800
2018-12-06 2018-11-26 B Purchase Schwartz Aharon Non-Executive Director
50,000 +inf%
3.89
US$194,600 		50,000 +inf% 3.89 US$194,600
2018-11-20 2018-11-19 S Sale Domzalski David

CEO

Executive Director
5,036 -3.3%
3.90
US$19,640 		5,036 -3.3% 3.90 US$19,640
2018-11-20 2018-11-19 S Sale Howard Alvin D

VP Regulatory

Officer
3,375 -8.1%
3.90
US$13,162 		3,375 -8.1% 3.90 US$13,162
2018-11-13 2018-11-08 S Sale Domzalski David

CEO

Executive Director
2,062 -1.3%
4.58
US$9,444 		2,062 -1.3% 4.58 US$9,444
2018-11-13 2018-11-08 S Sale Stuart Iain

SVP R&D

Officer
683 -2.0%
4.58
US$3,128 		683 -2.0% 4.58 US$3,128
2018-10-02 2018-10-01 S Sale Domzalski David

CEO

Executive Director
601 -0.4%
5.81
US$3,492 		601 -0.4% 5.81 US$3,492
2018-10-02 2018-10-01 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.81
US$825 		142 -1.1% 5.81 US$825
2018-10-02 2018-10-01 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.81
US$1,360 		234 -0.6% 5.81 US$1,360
2018-09-06 2018-09-04 S Sale Domzalski David

CEO

Executive Director
67 -0.0%
5.67
US$380 		67 -0.0% 5.67 US$380
2018-08-09 2018-08-08 S Sale Domzalski David

CEO

Executive Director
8,238 -5.1%
5.68
US$46,792 		8,238 -5.1% 5.68 US$46,792
2018-08-09 2018-08-08 S Sale Stuart Iain

SVP R&D

Officer
2,715 -7.3%
5.68
US$15,421 		2,715 -7.3% 5.68 US$15,421
2018-07-03 2018-07-02 S Sale Domzalski David

CEO

Executive Director
602 -0.4%
5.10
US$3,070 		602 -0.4% 5.10 US$3,070
2018-07-03 2018-07-02 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.10
US$724 		142 -1.1% 5.10 US$724
2018-07-03 2018-07-02 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.10
US$1,193 		234 -0.6% 5.10 US$1,193
2018-06-04 2018-06-01 S Sale Domzalski David

CEO

Executive Director
67 -0.0%
5.26
US$352 		67 -0.0% 5.26 US$352
2018-05-31 2018-05-13 S Sale Hirsch Stanley Non-Executive Director
6,164 -48.6%
5.09
US$31,369 		6,164 -48.6% 5.09 US$31,369
2018-04-04 2018-04-02 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.08
US$1,189 		234 -0.6% 5.08 US$1,189
2018-04-04 2018-04-02 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.08
US$721 		142 -1.1% 5.08 US$721
2018-04-04 2018-04-02 S Sale Domzalski David

CEO

Executive Director
602 -0.4%
5.08
US$3,058 		602 -0.4% 5.08 US$3,058
2018-03-06 2018-03-02 S Sale Elliott Russell P.

VP Drug Development
817 -6.0%
6.14
US$5,016 		817 -6.0% 6.14 US$5,016
2018-03-05 2018-03-01 S Sale Domzalski David

CEO

Executive Director
66 -0.0%
5.95
US$393 		66 -0.0% 5.95 US$393
2018-01-18 2018-01-11 PlS Planned sale Eini Meir
5,000 -0.2%
6.33
US$31,658 		5,000 -0.2% 6.33 US$31,658
2018-01-18 2018-01-10 PlS Planned sale Eini Meir
5,000 -0.2%
6.05
US$30,227 		5,000 -0.2% 6.05 US$30,227
2018-01-18 2018-01-09 PlS Planned sale Eini Meir
5,000 -0.2%
6.10
US$30,520 		5,000 -0.2% 6.10 US$30,520
2018-01-18 2018-01-08 PlS Planned sale Eini Meir
5,000 -0.2%
6.17
US$30,850 		5,000 -0.2% 6.17 US$30,850
2018-01-18 2018-01-05 PlS Planned sale Eini Meir
5,000 -0.2%
6.58
US$32,882 		5,000 -0.2% 6.58 US$32,882
2018-01-18 2018-01-04 PlS Planned sale Eini Meir
5,000 -0.2%
6.68
US$33,411 		5,000 -0.2% 6.68 US$33,411
2018-01-18 2018-01-03 PlS Planned sale Eini Meir
5,000 -0.2%
6.26
US$31,310 		5,000 -0.2% 6.26 US$31,310
2018-01-18 2018-01-02 PlS Planned sale Eini Meir
5,000 -0.2%
6.18
US$30,902 		5,000 -0.2% 6.18 US$30,902
Explore more

More insider trading research around Foamix Pharmaceuticals Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America